Loading...
NPI 1710516455 · Chicago, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Chicago Laboratory Consultant LLC is a clinical medical laboratory provider located in Chicago, Illinois. This profile covers 1 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Chicago Laboratory Consultant LLC |
| Address | 111 N Wabash Ave Ste 1605 |
| City | Chicago |
| State | IL |
| ZIP | 60602 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 5, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $18.4M |
| Medicaid | $10.4K |
CHICAGO LABORATORY CONSULTANT LLC’s Medicare billing is overwhelmingly concentrated in a single service line: the provider reported $18.4M in total Medicare revenue with its top code K1034 accounting for 100.0% of that Medicare revenue. The K1034 description (provision of nonprescription self-administered COVID-19 tests) indicates the entity operates primarily as a distributor or processor of COVID-19 testing kits for Medicare beneficiaries rather than a diversified clinical lab delivering a broad panel of diagnostic testing. This concentrated code mix suggests operations geared to high-volume, standardized test provisioning.
The Medicaid activity for this provider is de minimis relative to Medicare: total Medicaid revenue is $10.4K, and the same single code K1034 represents 100.0% of Medicaid revenue as well. This extreme payer-skew — $18.4M Medicare vs $10.4K Medicaid — indicates the organization is effectively single-payer dominant with respect to scale, relying almost entirely on Medicare fee-for-service receipts for its reported business.
Revenue concentration risk is high because the precomputed top-3 share for Medicare is 100.0%, meaning the provider’s entire Medicare business depends on the K1034 code. Any policy, reimbursement, or demand shifts affecting nonprescription self-administered COVID-19 tests could disproportionately impact this provider’s Medicare revenue. The same single-code concentration applies to Medicaid where K1034 also accounts for 100.0% of the small Medicaid revenue base.
On national competitive standing for the Medicare market the provider is an outlier: the K1034 volume places CHICAGO LABORATORY CONSULTANT LLC at rank #20 of 30,143 providers nationally and is described as an extreme outlier and ‘‘far above typical national volume’’ for this code. That rank and descriptor indicate this entity is a major national participant for K1034 volume, operating at a scale substantially above most other providers offering the same service.
By contrast, its Medicaid standing in-state for the same code is routine: K1034 ranks #12 of 59 providers in Illinois and is characterized as typical or unremarkable volume (81th percentile). This suggests the provider’s market dominance is concentrated in the national Medicare channel for this code, while its Medicaid footprint is modest and consistent with many in-state peers.
The operational profile implied by the code mix and volumes — extremely high Medicare K1034 claim count (1.6M claims) with average paid/claim of $12 and Medicaid 2.7K claims at $4 average — points to a high-throughput, low-margin model focused on standardized, widely distributed COVID-19 test units. The provider’s revenue generation appears to depend on scale rather than high per-claim reimbursement.
Tenure is relatively recent: the NPI was enumerated on 2020-04-05 (~6 years ago), which aligns with the pandemic-era timing for widespread COVID-19 test distribution. The timing supports a business build centered on pandemic response products and suggests growth in the years immediately following 2020 is likely tied to demand for K1034 services.
Given the identical top code across both payers and the precomputed fact that the top three codes account for 100.0% of revenue on each payer, the provider’s service diversification is minimal. For payer/provider analysts this profile signals that monitoring changes to K1034 reimbursement, clinical guidelines, or Medicare program rules should be prioritized when assessing financial or operational risk for this entity.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,564,640 | $10 | $18.8M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 8 | 1,150 | 720 | $10 | $414.9K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,690 | $1 | $10.8K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 12 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Chicago Laboratory Consultant LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| City Of Chicago | IL | Ambulance | $12.2M | $1.2B |
| Kaizen Health, Inc. | IL | Non-emergency Medical Transport (VAN) | $0 | $9.3M |
| Michael Friedman | IL | Otolaryngology Physician | $1.8M | $6.7K |
| Adam Levy | IL | Otolaryngology Physician | $124.6K | $837.4K |
| T Venkatesan | IL | Otolaryngology Physician | $229K | $357.5K |
| Krystle Miles | IL | Family Medicine Physician | $300K | $26.6K |
| Nehal Sheth | IL | Podiatrist | $177.2K | $28.4K |
| David Shanker | IL | Dermatology Physician | $179.6K | $0 |
| David Altman | IL | Anesthesiology Physician | $67.2K | $0 |
| Charles Turk | IL | Psychiatry Physician | $34.4K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.